Veradermics, Incorporated announced the pricing for its upsized initial public offering, setting the sale of 15,077,647 shares of common stock at $17.00 per share. At that price and share count, the company expects to generate roughly $256.3 million in gross proceeds prior to the deduction of underwriting discounts and other offering-related expenses.
The company has indicated plans for its common stock to begin trading on the New York Stock Exchange on February 4, 2026, using the ticker symbol "MANE." Subject to customary closing conditions, the offering is scheduled to close on February 5, 2026.
As part of the arrangement with underwriters, Veradermics granted a 30-day option that would allow them to purchase up to an additional 2,261,647 shares at the initial public offering price, less underwriting discounts and commissions. That overallotment provision is a standard mechanism that can increase the total shares sold if exercised.
Jefferies, Leerink Partners, Citigroup, and Cantor are listed as joint book-running managers for the offering.
Veradermics describes itself as a biopharmaceutical company founded by dermatologists, focused on developing therapeutics for aesthetic and dermatological conditions. The firm's lead program is VDPHL01, an oral, extended-release formulation of minoxidil being advanced as a non-hormonal option to treat pattern hair loss in both men and women.
Registration statements covering the shares have been filed with the Securities and Exchange Commission and are effective. The company has stated that the offering information is based on its press release.
Relevant context and next steps
- The offering price and expected gross proceeds are stated before underwriting discounts and offering expenses are deducted.
- Trading commencement on the NYSE is targeted for February 4, 2026, with the expected closing date of February 5, 2026, subject to standard closing conditions.
- An underwriters' 30-day option could add up to 2,261,647 shares at the same IPO price, less applicable fees.